抗精神病药物作用、新治疗靶点及当前临床试验设计在评估新靶点分子中的失败
该综述指出,自氯丙嗪偶然发现以来,D2受体拮抗剂虽能有效控制精神分裂症阳性症状,却无法改善认知与阴性缺损。临床前研究提示海马过度活跃和GABA能抑制丧失驱动多巴胺系统失调,靶向海马兴奋性的新化合物有望恢复抑制并改善症状。新型药物临床试验失败可能与既往D2拮抗剂暴露导致突触后超敏有关,而非药物无效,强调试验设计需考虑治疗史。
要点
- D2受体拮抗剂有效改善阳性症状,但对认知和阴性症状无效。
- 海马过度活跃和GABA能抑制丧失是多巴胺失调的上游机制。
- 新药试验失败或与既往D2拮抗剂暴露致突触后超敏有关。
核心结论
- 靶向海马上游病理有望开发更有效且副作用更少的精神分裂症治疗。
- 新型药物临床试验失败可能源于既往D2拮抗剂暴露而非缺乏疗效。
研究设计与样本
- 综述临床前研究和临床试验证据,探讨抗精神病药物作用机制与新靶点。
主要发现
- 抗精神病药物诱导多巴胺神经元去极化阻滞,正常化多巴胺过度活跃但不纠正海马功能障碍。
- 海马过度活跃和parvalbumin GABA能神经元抑制丧失驱动多巴胺系统失调。
- GABA α5正向变构调节剂和evenamide等化合物可恢复海马抑制并改善症状。
关键数值与推荐
- 临床前模型显示靶向海马兴奋性的化合物可能恢复抑制并正常化多巴胺活动。
临床怎么用
- 评估新化合物时需考虑患者既往抗精神病药物暴露史。
- 临床试验设计应纳入既往D2拮抗剂暴露因素。
局限性
- 证据主要来自临床前研究,临床转化仍需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The discovery of antipsychotic drugs more than 65 years ago revolutionized the treatment of schizophrenia that was initially based on serendipitous findings with chlorpromazine. This later led to the dopamine (DA) hypothesis, linking hyperdopaminergic states to psychosis. While D2-based antipsychotics effectively reduce positive symptoms, they fail to address cognitive and negative deficits. Preclinical studies have provided critical insights into schizophrenia pathophysiology and treatment. These studies show that hippocampal hyperactivity and loss of parvalbumin GABAergic (gamma-aminobutyric acidergic) neuron inhibition drive DA system dysregulation, which leads to pathological hyper-responsivity to stimuli. Antipsychotic drugs induce depolarization block in DA neurons that normalizes DA hyperactivity but does not correct upstream hippocampal dysfunction. Preclinical models have also identified potential novel treatments targeting the hippocampal hyperexcitability, including GABA α5-positive allosteric modulators and evenamide. These compounds may have the ability to restore hippocampal inhibition, normalize positive symptom-related DA activity, and improve cognitive and negative symptoms without D2-associated side effects. Clinical trial failures of novel agents, such as pomaglumetad, may be a product of prior D2 antagonist exposure leading to postsynaptic supersensitivity rather than lack of efficacy. This evidence underscores the importance of patient treatment history and the design of trials that account for prior antipsychotic exposure when evaluating new compounds. Targeting upstream pathology in the hippocampus offers a promising approach for developing more effective, side effect-sparing treatments for schizophrenia.
引用
- Grace AA, Uliana DL. Antipsychotic Drug Action, Novel Treatment Targets, and the Failure of Current Clinical Trial Designs in Evaluating New Target Molecules. Biol Psychiatry. 2026. PMID: 42320782. doi:10.1016/j.biopsych.2026.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。